Key points from this report:
- Buy Pacira Biosciences (PCRX). The stock is actionable after breaking out of a 13-week consolidation base on above average volume. Buy at current levels or on any constructive pullback to the rising 10-DMA.
- Strong post COVID-19 recovery. Exparel net product sales for October came in at $40.7M (+112% y/y). The drug has outpaced the elective surgery market throughout the pandemic. According to weekly data from mid-October, elective surgery procedures in the U.S. were down 26% while Exparel sales were up 13%. Management believes 90%+ of delayed procedures will be performed this year, with 2021 a substantial improvement over 2020.
- No competition until mid-2021. The U.S. FDA has classified Heron Therapeutics’ (HRTX) application for HTX-011 as class-2 submission, which indicates the agency could take up to six months to review the new information.
- Looking forward. The company will announce Q4 results in February. For 2020, consensus expects revenue and EPS growth of 2% and 26%, y/y, respectively. Consensus expects 2021 revenue and EPS growth of 26% and 74%, y/y, respectively
- See other ideas in our O’Neil Health Care Weekly